natgillin/translations-raw huggingface dataset:
For de primære metabolitter, 7α-thiomethyl-spironolakton og canrenon opnås gennemsnitlige Cmax-værdier på 382 μg/l og 94 μg/l efter henholdsvis 2 og 4 timer.
Mean Cmax of 382 μg/l and 94 μg/l are achieved for the primary metabolites, 7α- thiomethyl-spironolactone and canrenone, after 2 and 4 hours, respectively.
For de to undersøgelser tilsammen var den totale responsandel på analysetidspunktet 66 % (263 ud af 398 patienter), og de indledende resultater viser, at responsen i gennemsnit varede i 8,5 måneder.
Combining both studies, the overall response rate at the time of analysis was 66% (263 out of 398 patients) and preliminary data suggest that the average length of response was 8.5 months.
For de tre sidste polysakkarider (1, 5 og 7F) udløste Synflorix effektivt produktionen af antistoffer.
For the three additional polysaccharides (1, 5, 7F), Synflorix was effective in triggering the production of antibodies.
For de øvrige komponenter:
For the other components:
for den adjuverende behandling af patienter, som er opereret for stadium III (Dukes stadium C) kolonkræft (se pkt.
for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer (see section 5.1).
For den inaktive hovedmetabolit nalmefen-3-O-glukuronid var AUC og Cmax op til hhv.
For the inactive major metabolite nalmefene 3-O-glucuronide, the AUC and Cmax were up to 5.1 times and
For den indledende dosistitrering i denne gruppe anbefales det, at Otezla kun titreres med AM-skemaet, som er anført i tabel 1, og at PM-doserne springes over (se pkt.
For initial dose titration in this group, it is recommended that Otezla be titrated using only the AM schedule listed in Table 1 and the PM doses be skipped (see section 5.2).
For den samlede population var mortaliteten for hospitalsindlagte signifikant lavere for patienter i behandling med Xigris end for placebo (29,4 % versus 34,6 %, p=0,023).
In the overall population, the in-hospital mortality was significantly lower in patients on Xigris than in patients on placebo (29.4% vs.
For den samlede population viste Mirvaso desuden statistisk signifikant overlegenhed (p<0,001) i forhold til placebo-gel med hensyn til en hurtig initial indtræden af en klinisk relevant effekt (grad 1 sammensat forbedring for CEA og PSA) efter den første applikation efter 30 minutter på dag 1 (sekundært endepunkt 27,9 % vs.
In addition, for the overall population, Mirvaso demonstrated statistical superiority (p<0.001) over vehicle gel with respect to rapid initial onset of a clinically meaningful effect (1-Grade Composite Success for CEA and PSA) after the first application at 30 minutes on Day 1(secondary endpoint 27.9% vs.
For den samme behandlingsarm opstod der recidiv hos 4/13 (31 %) patienter med baseline-NS5A-RAVs, der gav >100 gange større ændring, sammenlignet med 3/95 (3 %) hos patienter uden nogen baseline RAVs eller RAVs, der gav ≤100 gange mindre ændring.
For the same treatment arm, patients with baseline NS5A RAVs conferring a fold-change of > 100, relapse occurred in 4/13 (31%), as compared to 3/95 (3%) in those without any baseline RAVs or RAVs conferring a fold-change of ≤ 100.
For den totale studiepopulation var smerteintensiteten statistisk signifikant lavere for Ilaris 150 mg sammenlignet med triamcinolonacetonid ved 72 timer.
For the overall study population, pain intensity was statistically significantly lower for Ilaris 150 mg compared with triamcinolone acetonide at 72 hours.
For det andet endepunkt – IPD – var der 35 (7 for Prevenar 13; 28 for placebo) første episoder af VT-IPD, hvilket resulterede i en effekt på 75,00 % (95,2 % CI; 41,06-90,87; p=0,0005).
For the IPD secondary endpoint, there were 35 (7 Prevenar 13: 28 Placebo) first episodes of VT-IPD, resulting in an efficacy of 75.00% (95.2% CI, 41.06-90.87; p=0.0005).
For det andet hæmmer pravastatin dannelsen af LDL ved at hæmme leversyntesen af VLDL-kolesterol, som et forstadie for LDL-kolesterol.
Secondly, pravastatin inhibits LDL production by inhibiting the hepatic synthesis of VLDL- cholesterol, the LDL-cholesterol precursor.
For det primære endepunkt (per protokol- population) var der 139 (49 for Prevenar 13; 90 for placebo) første episoder af VT-CAP, hvilket resulterede i en effekt på 45,56 % (95,2 % CI; 21,82-62,49; p=0,0006).
For the primary endpoint (per protocol population), there were 139 (49 Prevenar 13: 90 Placebo) first episodes of VT-CAP resulting in an efficacy of 45.56% (95.2% CI, 21.82-62.49; p=0.0006).
For detaljerede instruktioner henvises til indlægssedlen.
For detailed instructions, please refer to the patient leaflet.
For detaljeret information, se produktresuméet for YTRACIS.
For detailed information refer to the Summary of Product Characteristics of YTRACIS.
For dette lægemiddel er den effektive dosisækvivalent fra en administreret aktivitet på 750 MBq typisk 7,7 mSv for en person på 70 kg.
For this medicinal product, the effective dose equivalent resulting from an administered activity of 750 MBq is typically 7.7 mSv for a 70 kg individual.
For dette produkt kræves en Officiel batch frigivelse.
Official control authority batch release is required for this product.
For dette produkt, er den effektive dosis efter administration af en aktivitet på 555 - 740 MBq typisk 8,88-11,84 mSv for en person på 70 kg.
For this product, the effective dose resulting from an administered activity of 555-740 MBq is typically 8.88–11.84 mSv for a 70 kg individual.
For diagnostiske nuklearmedicinske undersøgelser antyder den nuværende dokumentation, at de utilsigtede virkninger optræder med lav frekvens som følge af de lave strålingsdoser, der gives.
For diagnostic nuclear medicine investigations, the current evidence suggests that the adverse effects will occur with low frequency because of the low radiation doses incurred.
For diagnostiske nuklearmedicinske undersøgelser tyder de nuværende beviser på, at disse bivirkninger vil opstå med lav hyppighed, på grund af den lave strålingsdosis, patienterne udsættes for.
For diagnostic nuclear medicine investigations, the current evidence suggests that these adverse events will occur with low frequency because of the low radiation doses incurred.
for diltiazem/atazanavir er CYP3A4-
diltiazem/atazanavir interaction is
For din første injektion, gå direkte til Afsnit 3 – Trin C.
For your first injection go directly to Section 3 - Step C.
For din første injektion, gå direkte til Afsnit 3 – Trin C.
For your first injection go directly to Section 3 – Step C.
For disse kvinder kan YENTREVE nok ikke yde nogen fordele udover det som konservativ livsstilsomlægninger kan bidrage med.
In these women, YENTREVE may provide no benefit beyond that afforded by more conservative behavioural interventions.
for disse lægemidler.
for either medicinal product.
For disse patienter bevirkede tillæg af Fuzeon ikke en øgning af tilfælde af leverrelaterede bivirkninger.
In these the addition of Fuzeon did not increase the incidence of hepatic events.
For DLCO's vedkommende var reduktionerne ved måned 24 3,3 % for fingolimod 0,5 mg og 2,7 % for placebo.
For DLCO the reductions at Month 24 were 3.3% for fingolimod 0.5 mg and 2.7% for placebo.
For docetaxel /Carboplatin-kombinationen kunne der hverken bevises ekvivalent eller non- inferior effekt sammenlignet med referencebehandlingen kombination VCis.
For docetaxel/carboplatin combination, neither equivalent nor non-inferior efficacy could be proven compared to the reference treatment combination VCis.
For dosen 1,0 g/kg kan der foretages en tilsvarende justering af volumen, eller der kan anvendes andre styrker, som vist i Tabel 2.
For the 1.0 µg/kg dose, similar volume adjustments can be made or alternate strengths can be used as shown in Table 2.
For dosen, som skal indgives, se anbefalet dosering i afsnit 4.2.
For the dose to be administered, see recommended posology in section 4.2.
For dosen, som skal indgives, se den anbefalede dosering i afsnit 3 ”Sådan gives HUMENZA”.
For the dose to be administered, see recommended posology in section 3 “How HUMENZA is given”.
For doser < 90 mg: fortynd Caelyx i 250 ml 5 % (50 mg/ml) glucoseinfusionsvæske.
For doses < 90 mg: dilute Caelyx in 250 ml 5% (50 mg/ml) glucose solution for infusion.
For doser mellem 120 mg og 300 mg blev der observeret en større end dosisproportional stigning i febuxostats AUC.
For doses between 120 mg and 300 mg, a greater than dose proportional increase in AUC is observed for febuxostat.
For doser mindre end 100 mg eller doser, som ligger imellem 100 mg mængderne, blandes hele indholdet af hvert brev med en væske og herefter doseres med det relevante ml volumen, som din læge har fortalt dig ved brug af den orale doseringssprøjte.
For doses less than 100 mg amounts or doses between 100 mg amounts, the content of the entire sachet is to be mixed with a liquid and then dosed by the appropriate mL volume as told to you by your doctor using the oral dosing syringe.
For doser over 20 mg forøgedes AUC mindre end proportionalt.
AUC increased less than in proportion to dose above 20 mg.
For doser  90 mg: fortynd Caelyx i 500 ml 5 % (50 mg/ml) glucoseinfusionsvæske.
For doses  90 mg: dilute Caelyx in 500 ml 5% (50 mg/ml) glucose solution for infusion.
For dosisjustering af docetaxel og anden kemoterapi, se det relevante produktresumé.
For docetaxel and other chemotherapy dose modifications, see relevant summary of product characteristics (SmPC).
for dosisjustering.
recommendations.
For E. coli, Campylobacter og Enterococci, blev både vild- og ikke vild-fænotyper observerede (MIC-værdier mellem 1- >64µg/ml).
For E. coli, Campylobacter and Enterococci, both wild type and non-wild type phenotypes were observed (MIC range 1– > 64 µg/ml).
For E. coli, Campylobacter og Enterococci, blev både vild- og ikke vild-fænotyper observerede (MIC-værdier mellem 1->64µg/ml).
For E. coli, Campylobacter and Enterococci, both wild type and non-wild type phenotypes were observed (MIC range 1–> 64 µg/ml).
for efavirenz genoptages.
initial dose of efavirenz should
for efavirenz, når det gives
for any of these medicinal
For efterfølgende doser lå den gennemsnitlige totale clearance på 15-32 l/t. og 18-32 l/t. for doser på henholdsvis 1,0 mg/m2 og 1,3 mg/m2.
1.3 mg/m2, respectively, and ranged from 15 to 32 l/h and 18 to 32 l/h following subsequent doses for doses of 1.0 mg/m2 and 1.3 mg/m2, respectively.
For eksempel beregnes antallet af hætteglas til en startdosis hos en person på 70 kg på følgende måde:
e.g. for a 70 kg subject the number of vials for an initial dose will be calculated as follows:
For eksempel er dannelse af antistoffer (også kaldet inhibitorer) mod faktor IX en kendt komplikation, der kan opstå under behandling af hæmofili B. Antistofferne forhindrer, at behandlingen virker korrekt.
For example, the formation of antibodies (also known as inhibitors) to factor IX is a known complication that can occur during the treatment of haemophilia B. The antibodies prevent the treatment from working properly.
For eksempel er dannelsen af antistoffer (også kaldet inhibitorer) mod faktor VIII en kendt komplikation, der kan opstå under behandlingen af hæmofili A. Antistofferne forhindrer, at ELOCTA virker korrekt.
For example, the formation of antibodies (also known as inhibitors) to factor VIII is a known complication that can occur during the treatment of haemophilia A. The antibodies prevent ELOCTA from working properly.
For eksempel kan du tage SIRTURO mandag, onsdag og fredag hver uge fra og med den 3. uge.
For example, you may take SIRTURO on Monday, Wednesday and Friday every week from week 3 onwards.
For eksempel skal der 1 pakning med 80 mg og 3 med 20 mg til en dosis på 140 mg docetaxel Den rekonstituerede opløsning indeholder ca.
For example, a dose of 140 mg docetaxel would require one 80 mg and three 20 mg packs.
For eksempel skal der til en beregnet dosis på 140 mg udtages 14 ml præmix.
For example, a dose of 140 mg docetaxel would require 14 ml docetaxel premix solution.
For eksempel var incidensen af træthed, feber, myalgi, neutropeni/anæmi, anoreksi, kvalme og opkastning, diarré, kulderystelser, influenzalignende symptomer, depression, alopeci, smagsforstyrrelser og svimmelhed i en undersøgelse af højdosis adjuverende IntronA-behandling hos patienter med melanom større end i hepatitis C undersøgelserne.
For example, in a trial of high-dose adjuvant IntronA treatment in patients with melanoma, incidences of fatigue, pyrexia, myalgia, neutropaenia/anaemia, anorexia, nausea and vomiting, diarrhoea, chills, flu- like symptoms, depression, alopecia, altered taste, and dizziness were greater than in the hepatitis C trials.
For eksempel, for en baby der vejer 3 kg, bliver udregningen: (3 x 0,15) ml = 0,45 ml palivizumab pr. måned
For example, for a baby with a body weight of 3 kg, the calculation becomes: (3 x 0.15) mL = 0.45 mL palivizumab per month
For eksempel, for en baby der vejer 3 kg, bliver udregningen: (3 x 0,15) ml = 0,45 ml palivizumab pr. måned
For example, for a baby with a body weight of 3 kg, the calculation becomes: (3 x 0.15) mL = 0.45 mL palivizumab per month.
For eksempel: 25 ml koncentrat indeholder 500 mg dalbavancin.
For example: 25 ml of the concentrate contains 500 mg dalbavancin.
For ektoparasitter er der udført en feltundersøgelse med 324 hunde, der var angrebet af lopper og/eller flåter, og som blev behandlet én gang med Nexgard Spectra eller med et spot-on-produkt med pyriprol til kontrol af lopper og flåter.
For ectoparasites a field study involved 324 dogs with flea and/or tick infestations that were given a single treatment with Nexgard Spectra or a spot-on medicine containing pyripole that controls fleas and ticks.
For en lille procentdel af D3- vitamin sker der en glucuronidisering før elimination.
A small percentage of vitamin D3 undergoes glucuronidation prior to elimination.
For en monovalent vaccine, som indeholder inaktiveret bluetonguevirus serotype 4, er én injektion tilstrækkelig.
For a monovalent vaccine containing an inactivated Bluetongue Virus serotype 4, one injection is sufficient.
For en OptiSet der allerede er taget i brug: Vælg en dosis på 2 enheder ved at dreje dosisskalaen fremad indtil doseringspilen står ud for tallet 2.
In-use OptiSet: select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2.
For en OptiSet, der allerede er taget i brug: Vælg en dosis på 2 enheder ved at dreje dosisskalaen fremad indtil doseringspilen står ud for tallet 2.
In-use OptiSet: select a dose of 2 units by turning the dosage selector forward till the dose arrow points to 2.
For en oversigt over kontraindikationerne for pegyleret interferon-alfa og ribavirin henvises til produktresuméerne for disse, eftersom INCIVO skal anvendes i kombination med pegyleret interferon-alfa ogribavirin.
Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin for a list of their contraindications since INCIVO must be used in combination with peginterferon alfa and ribavirin.
For en sikkerheds skyld anbefales det at undgå ataluren under graviditeten.
As a precautionary measure, it is recommended to avoid the use of ataluren during pregnancy.
For en sikkerheds skyld anbefales det, at man ikke bader dyr inden for 2 dage efter påføring.
As a precaution, it is not recommended to bathe animals within 2 days after topical treatment.
For en sikkerheds skyld bør Cosentyx undgås under graviditet.
As a precautionary measure, it is preferable to avoid the use of Cosentyx in pregnancy.
For en sikkerheds skyld bør Lonquex undgås under graviditeten.
As a precautionary measure, it is preferable to avoid the use of Lonquex during pregnancy.
For en sikkerheds skyld bør SIRTURO undgås under graviditet, medmindre fordelene ved behandlingen anses at opveje risikoen.
As a precautionary measure, it is recommended to avoid the use of SIRTURO during pregnancy unless the benefit of therapy is considered to outweigh the risks.
For en sikkerheds skyld bør vernakalant undgås under graviditet.
As a precautionary measure, it is preferable to avoid the use of vernakalant during pregnancy.
For en sikkerheds skyld bør Zinforo undgås under graviditet, medmindre kvindens kliniske tilstand kræver behandling med et antibiotikum med Zinforos antibakterielle profil.
As a precautionary measure, it is preferable to avoid the use of Zinforo during pregnancy unless the clinical condition of the woman requires treatment with an antibiotic with Zinforo’s antibacterial profile.
For en sikkerheds skyld skal amning ophøre under behandling med Oncaspar og må ikke starte igen efter seponering af Oncaspar.
As a precautionary measure, breast-feeding should be discontinued during treatment with Oncaspar and should not be restarted after discontinuation of Oncaspar.
For en sikkerheds skyld skal amning ophøre under behandling med Oncaspar og må ikke startes igen, efter at behandlingen med Oncaspar er ophørt.
As a precautionary measure, breast feeding should be discontinued during treatment with Oncaspar and should not be re-started after treatment with Oncaspar is discontinued.
For en sikkerhedsskyld bør SonoVue undgås under graviditeten.
As a precautionary measure, it is preferable to avoid the use of SonoVue during pregnancy.
For en subkutan dosis på 60 mg sås maksimale serumkoncentrationer af denosumab (Cmax) på 6 μg/ml (interval 1-17 μg/ml) efter 10 dage (interval 2-28 dage).
For a 60 mg subcutaneous dose, maximum serum denosumab concentrations (Cmax) of 6 μg/ml (range 1-17 μg/ml) occurred in 10 days (range 2-28 days).
For enkeltdosisnæsesprayen skal alle ubrugte næsesprays eller tomme beholdere returneres i henhold til de lokale retningslinjer.
For the single-dose nasal spray all unused devices or empty containers should be returned systematically according to the local regulation.
For enkeltdosisnæsesprayen skal alle ubrugte næsesprays eller tomme beholdere returneres i henhold til de lokale retningslinjer.
That for the single-dose nasal spray all unused devices or empty containers should be returned systematically according to the local regulation.
For enkeltdosisnæsesprayen skal alle ubrugte næsesprays og tomme beholdere returneres i henhold til de lokale retningslinjer.
For the single-dose nasal spray all unused devices or empty containers should be returned systematically according to the local regulation.
For enkelte patienter kan ekstra
Individual patients may
For enkelte patienter var WHO- funktionsklassen ukendt (3/234, 1,3%).
0.4 %); for a few patients (3/234, 1.3 %), the WHO Functional Class was unknown.
For EORTC QLQ-C30 rapporterede patienter i ramucirumab plus FOLFIRI-armen om et forbigående fald i QoL på de fleste af skalaerne sammenlignet med patienter i placebo plus FOLFIRI-armen.
For the EORTC QLQ-C30, patients in the ramucirumab plus FOLFIRI treatment arm reported a transient decrease in QoL compared to the patients in the placebo plus FOLFIRI treatment arm in most of the scales.
For evaluerbare forsøgspersoner, der indgik i armen med profylakse med fast ugentligt interval i studie I, var den mediane ugentlige dosis 45,17 IU/kg (interkvartilt interval 38,1-53,7).
For evaluable subjects enrolled in the prophylaxis fixed weekly interval arm of study I, the median weekly dose was 45.17 IU/kg (interquartile range 38.1-53.7).
For evaluerbare forsøgspersoner, der indgik i armen med profylakse med individuelle intervaller i studie I, var det mediane interval 12,53 dage (interkvartilt interval 10,4-13,4).
For evaluable subjects enrolled in the prophylaxis individualised interval arm of study I, the median interval was 12.53 days (interquartile range 10.4-13.4).
For fertile kvinder
For females of childbearing potential
For flasker af hvidt højdensitetspopyethylen:
For white high-density polyethylene bottles:
For flasker: Skal anvendes inden for 100 dage efter anbrud.
For Bottle packs: After first opening use within 100 days.
For flasker: Skal anvendes inden for 100 dage efter åbning.
For bottle packs: After first opening use within 100 days.
For flerdosisnæsesprayen og flerdosisnæsespray DoseGuard skal alle brugte næsesprays eller tomme beholdere returenres i henhold til de lokale retningslinjer.
For the multi-dose nasal spray and multi-dose nasal spray DoseGuard all unused devices or empty containers should be returned systematically according to the local regulation.
For flerdosisnæsesprayen og flerdosisnæsespray DoseGuard skal alle brugte næsesprays eller tomme beholdere returneres i henhold til de lokale retningslinjer.
For the multi-dose nasal spray and multi-dose nasal spray DoseGuard all unused devices or empty containers should be returned systematically according to the local regulation.
For flerdosisnæsesprayen og flerdosisnæsespray DoseGuard skal alle ubrugte næstesprays eller tomme beholdere returneres ifølge de lokale retningslinjer.
That for the multi-dose nasal spray and multi-dose nasal spray DoseGuard all unused devices or empty containers should be returned systematically according to the local regulation.
For flåter var Broadline 85-93 % effektivt, mod 92-98 % for katte behandlet med sammenligningsproduktet.
For ticks effectiveness was between 85 and 93% for Broadline-treated cats compared with 92 and 98% for cats treated with the comparator product.
For flåterne (I. ricinus) indtrådte virkningen inden for 12 timer, efter flåten havde bidt sig fast, i løbet af 28 dage efter hunden havde fået produktet.
For ticks (I. ricinus), the onset of efficacy is within 12 hours of attachment during the 28 day period after product administration.
For fuldstændig indikation, inkl. arter og larvestadier, læs indlægssedlen.
For the complete indication, including species and larval stages, read the package leaflet.
For fuldstændig information læs afsnittet ”Sådan skal du bruge” i indlægssedlen for interferon alfa-2b.
For complete information be sure to read the “How to use” section of the Package Leaflet for interferon alfa-2b.
For fuldstændig liste over hjælpestoffer se sektion 6.1.
For the full list of excipients, see section 6.1.
For fuldstændig sammensætning se sektion 6.1.
For a full list of excipients see section 6.1.
For fyldte injektionssprøjter Sanofi Winthrop Industrie 1051 Boulevard Industriel
Sanofi Winthrop Industrie 1051 Boulevard Industriel
For fyldte penne
For pre-filled pens
for fødedygtige kvinder skal der foreligge en negativ graviditetstest før påbegyndelse af behandlingen
For women of child-bearing potential a negative pregnancy test should be confirmed before starting treatment;
For generel information om Kivexa, kontakt GlaxoSmithKline Pharma A/S på tlf.: +45 36 35 91 00.
For general Kivexa information enquiries, contact [local company name and telephone number inserted here]
For generel information om Triumeq, kontakt: GlaxoSmithKline Pharma A/S på tlf.: +45 36 35 91 00.
For general Triumeq information enquiries, contact:
For generel information om Ziagen, kontakt GlaxoSmithKline Pharma A/S på tlf.: +45 36 35 91 00.
For general Ziagen information enquiries, contact GlaxoSmithKline….Tel …………… (local company name and telephone number will be inserted here).
For generel information om Ziagen, kontakt GlaxoSmithKline Pharma A/S på tlf.: +45 36 35 91 00.
For general Ziagen information enquiries, contact ……………….Tel …………… (local company name and telephone number will be inserted here).
For generelle kommentarer til behandling af patienter med samtidig hiv-infektion, inklusive diskussion af forskellige antiretrovirale regimer, som kan anvendes, se pkt.4.4 (behandling af patienter med samtidig hiv-infektion).
For a general comment on treatment of HIV co-infected patients, including a discussion on different antiretroviral regimens that may be used, please see section 4.4 (Treatment of HIV co-infected patients).
For god opblanding af multidosis hætteglas, anvend følgende procedure:
For proper reconstitution of the multidose vial, use the following procedure: